Shopping Cart 0
Cart Subtotal
USD 0

Ankylosing Spondylitis (Bekhterevs Disease)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 6, 5, 10, 1, 13, 6 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ankylosing Spondylitis (Bekhterev's Disease)-Overview 8

Ankylosing Spondylitis (Bekhterev's Disease)-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 13

Ankylosing Spondylitis (Bekhterev's Disease)-Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Ankylosing Spondylitis (Bekhterev's Disease)-Companies Involved in Therapeutics Development 24

AbbVie Inc 24

Adello Biologics LLC 24

Allergan Plc 25

Alteogen Inc 25

Amgen Inc 26

Biocad 26

Biocon Ltd 27

Bionovis SA 27

Celgene Corp 28

Coherus BioSciences Inc 28

Galapagos NV 29

Genor BioPharma Co Ltd 29

Immunwork Inc 30

Innovent Biologics Inc 30

Johnson & Johnson 31

Merck KGaA 31

Momenta Pharmaceuticals Inc 32

Mycenax Biotech Inc 32

Novartis AG 33

Oncobiologics Inc 33

Protalix BioTherapeutics Inc 34

Reliance Life Sciences Pvt Ltd 34

Sandoz International GmbH 35

Shanghai Pharmaceutical Co Ltd 35

Sun Pharma Advanced Research Company Ltd 36

UCB SA 36

Xbrane Biopharma AB 37

Ankylosing Spondylitis (Bekhterev's Disease)-Drug Profiles 38

adalimumab biosimilar-Drug Profile 38

adalimumab biosimilar-Drug Profile 40

adalimumab biosimilar-Drug Profile 41

adalimumab biosimilar-Drug Profile 42

adalimumab biosimilar-Drug Profile 43

adalimumab biosimilar-Drug Profile 44

adalimumab biosimilar-Drug Profile 45

adalimumab biosimilar-Drug Profile 47

adalimumab biosimilar-Drug Profile 50

adalimumab biosimilar-Drug Profile 51

adalimumab biosimilar-Drug Profile 52

adalimumab biosimilar-Drug Profile 54

adalimumab biosimilar-Drug Profile 55

adalimumab biosimilar-Drug Profile 56

apremilast-Drug Profile 57

BAT-1406-Drug Profile 68

BCD-085-Drug Profile 69

bimekizumab-Drug Profile 70

certolizumab pegol biosimilar-Drug Profile 72

DNX-114-Drug Profile 73

DNX-514-Drug Profile 74

etanercept biosimilar-Drug Profile 75

etanercept biosimilar-Drug Profile 77

etanercept biosimilar-Drug Profile 79

etanercept biosimilar-Drug Profile 80

etanercept biosimilar-Drug Profile 81

etanercept biosimilar-Drug Profile 82

etanercept biosimilar-Drug Profile 86

etanercept biosimilar-Drug Profile 87

etanercept biosimilar-Drug Profile 90

filgotinib-Drug Profile 91

golimumab-Drug Profile 103

golimumab biosimilar-Drug Profile 112

golimumab biosimilar-Drug Profile 113

HEISCO-III-002-Drug Profile 114

infliximab biosimilar-Drug Profile 115

infliximab biosimilar-Drug Profile 116

infliximab biosimilar-Drug Profile 117

infliximab biosimilar-Drug Profile 120

infliximab biosimilar-Drug Profile 121

infliximab biosimilar-Drug Profile 122

infliximab biosimilar-Drug Profile 123

risankizumab-Drug Profile 124

secukinumab-Drug Profile 128

TE-2122-Drug Profile 141

TE-2158-Drug Profile 142

thalidomide-Drug Profile 143

tildrakizumab-Drug Profile 144

upadacitinib tartrate-Drug Profile 147

VTP-43742-Drug Profile 151

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects 154

Ankylosing Spondylitis (Bekhterev's Disease)-Discontinued Products 156

Ankylosing Spondylitis (Bekhterev's Disease)-Product Development Milestones 157

Featured News & Press Releases 157

Appendix 169

Methodology 169

Coverage 169

Secondary Research 169

Primary Research 169

Expert Panel Validation 169

Contact Us 169

Disclaimer 170


List Of Figure

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by AbbVie Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Adello Biologics LLC, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Allergan Plc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Alteogen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Amgen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Biocad, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Biocon Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Bionovis SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Celgene Corp, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Coherus BioSciences Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Galapagos NV, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Genor BioPharma Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Immunwork Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Innovent Biologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Johnson & Johnson, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Merck KGaA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Mycenax Biotech Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Novartis AG, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Oncobiologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Sandoz International GmbH, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by UCB SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Xbrane Biopharma AB, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AbbVie Inc, Adello Biologics LLC, Allergan Plc, Alteogen Inc, Amgen Inc, Biocad, Biocon Ltd, Bionovis SA, Celgene Corp, Coherus BioSciences Inc, Galapagos NV, Genor BioPharma Co Ltd, Immunwork Inc, Innovent Biologics Inc, Johnson & Johnson, Merck KGaA, Momenta Pharmaceuticals Inc, Mycenax Biotech Inc, Novartis AG, Oncobiologics Inc, Protalix BioTherapeutics Inc, Reliance Life Sciences Pvt Ltd, Sandoz International GmbH, Shanghai Pharmaceutical Co Ltd, Sun Pharma Advanced Research Company Ltd, UCB SA, Xbrane Biopharma AB

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 6, 5, 10, 1, 13, 6 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ankylosing Spondylitis (Bekhterev's Disease)-Overview 8

Ankylosing Spondylitis (Bekhterev's Disease)-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 13

Ankylosing Spondylitis (Bekhterev's Disease)-Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Ankylosing Spondylitis (Bekhterev's Disease)-Companies Involved in Therapeutics Development 24

AbbVie Inc 24

Adello Biologics LLC 24

Allergan Plc 25

Alteogen Inc 25

Amgen Inc 26

Biocad 26

Biocon Ltd 27

Bionovis SA 27

Celgene Corp 28

Coherus BioSciences Inc 28

Galapagos NV 29

Genor BioPharma Co Ltd 29

Immunwork Inc 30

Innovent Biologics Inc 30

Johnson & Johnson 31

Merck KGaA 31

Momenta Pharmaceuticals Inc 32

Mycenax Biotech Inc 32

Novartis AG 33

Oncobiologics Inc 33

Protalix BioTherapeutics Inc 34

Reliance Life Sciences Pvt Ltd 34

Sandoz International GmbH 35

Shanghai Pharmaceutical Co Ltd 35

Sun Pharma Advanced Research Company Ltd 36

UCB SA 36

Xbrane Biopharma AB 37

Ankylosing Spondylitis (Bekhterev's Disease)-Drug Profiles 38

adalimumab biosimilar-Drug Profile 38

adalimumab biosimilar-Drug Profile 40

adalimumab biosimilar-Drug Profile 41

adalimumab biosimilar-Drug Profile 42

adalimumab biosimilar-Drug Profile 43

adalimumab biosimilar-Drug Profile 44

adalimumab biosimilar-Drug Profile 45

adalimumab biosimilar-Drug Profile 47

adalimumab biosimilar-Drug Profile 50

adalimumab biosimilar-Drug Profile 51

adalimumab biosimilar-Drug Profile 52

adalimumab biosimilar-Drug Profile 54

adalimumab biosimilar-Drug Profile 55

adalimumab biosimilar-Drug Profile 56

apremilast-Drug Profile 57

BAT-1406-Drug Profile 68

BCD-085-Drug Profile 69

bimekizumab-Drug Profile 70

certolizumab pegol biosimilar-Drug Profile 72

DNX-114-Drug Profile 73

DNX-514-Drug Profile 74

etanercept biosimilar-Drug Profile 75

etanercept biosimilar-Drug Profile 77

etanercept biosimilar-Drug Profile 79

etanercept biosimilar-Drug Profile 80

etanercept biosimilar-Drug Profile 81

etanercept biosimilar-Drug Profile 82

etanercept biosimilar-Drug Profile 86

etanercept biosimilar-Drug Profile 87

etanercept biosimilar-Drug Profile 90

filgotinib-Drug Profile 91

golimumab-Drug Profile 103

golimumab biosimilar-Drug Profile 112

golimumab biosimilar-Drug Profile 113

HEISCO-III-002-Drug Profile 114

infliximab biosimilar-Drug Profile 115

infliximab biosimilar-Drug Profile 116

infliximab biosimilar-Drug Profile 117

infliximab biosimilar-Drug Profile 120

infliximab biosimilar-Drug Profile 121

infliximab biosimilar-Drug Profile 122

infliximab biosimilar-Drug Profile 123

risankizumab-Drug Profile 124

secukinumab-Drug Profile 128

TE-2122-Drug Profile 141

TE-2158-Drug Profile 142

thalidomide-Drug Profile 143

tildrakizumab-Drug Profile 144

upadacitinib tartrate-Drug Profile 147

VTP-43742-Drug Profile 151

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects 154

Ankylosing Spondylitis (Bekhterev's Disease)-Discontinued Products 156

Ankylosing Spondylitis (Bekhterev's Disease)-Product Development Milestones 157

Featured News & Press Releases 157

Appendix 169

Methodology 169

Coverage 169

Secondary Research 169

Primary Research 169

Expert Panel Validation 169

Contact Us 169

Disclaimer 170


List Of Figure

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by AbbVie Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Adello Biologics LLC, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Allergan Plc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Alteogen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Amgen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Biocad, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Biocon Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Bionovis SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Celgene Corp, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Coherus BioSciences Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Galapagos NV, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Genor BioPharma Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Immunwork Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Innovent Biologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Johnson & Johnson, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Merck KGaA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Mycenax Biotech Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Novartis AG, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Oncobiologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Sandoz International GmbH, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by UCB SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline by Xbrane Biopharma AB, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Ankylosing Spondylitis (Bekhterev's Disease)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

AbbVie Inc, Adello Biologics LLC, Allergan Plc, Alteogen Inc, Amgen Inc, Biocad, Biocon Ltd, Bionovis SA, Celgene Corp, Coherus BioSciences Inc, Galapagos NV, Genor BioPharma Co Ltd, Immunwork Inc, Innovent Biologics Inc, Johnson & Johnson, Merck KGaA, Momenta Pharmaceuticals Inc, Mycenax Biotech Inc, Novartis AG, Oncobiologics Inc, Protalix BioTherapeutics Inc, Reliance Life Sciences Pvt Ltd, Sandoz International GmbH, Shanghai Pharmaceutical Co Ltd, Sun Pharma Advanced Research Company Ltd, UCB SA, Xbrane Biopharma AB